At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 288 enrolled
Drug / intervention
LY2216684 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Long-Term, Open-Label, Safety Study of LY2216684 12 to 18 mg Once Daily as Adjunctive Treatment for Adult Patients With Major Depressive Disorder Who Were Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment
In Brief
A Phase 3 clinical trial evaluating LY2216684 and SSRI for Major Depressive Disorder. Completed, enrolled 288 participants across 9 sites.
Detailed Summary
The primary objective of this study is to evaluate the long-term safety and tolerability of LY2216684 administered once daily in the adjunctive treatment with an Selective Serotonin Reuptake Inhibitors (SSRI) for up to approximately 1 year in participants with Major Depressive Disorder (MDD) who were partial responders to their SSRI treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMajor Depressive Disorder
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJun 2011
Enrollment StartAug 2011
Primary CompletionJan 2014
TodayJul 2026
First PostedJun 10, 2011
Enrollment StartAug 1, 2011
Primary CompletionJan 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 15.1 years ago
Interventions
LY2216684drug
SSRIdrug
Participants were to enter the study taking their current stable SSRI treatment dose and maintain the same dose throughout the study.